Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Galapagos creates Fidelta, a third Galapagos service division


Print article Print article
© Marketwire 2013
2013-01-15 07:38:20 -

MECHELEN, BELGIUM -- (Marketwire) -- 01/15/13 -- Galapagos NV (Euronext: GLPG) announced
today that the research site in Zagreb, Croatia, will form the basis of a
newly
created service division, called Fidelta. Next to BioFocus and Argenta,
this is
the third service division of Galapagos.



In September 2010 Galapagos acquired GlaxoSmithKline's state-of-the-art
research
center in Zagreb, Croatia, accessing capabilities to resource research
programs
from molecule through to the clinic for internal R&D programs. In
order to
enhance efficient use of these facilities, Galapagos has re-focused the
Zagreb
organization from internal to external outsourcing.



Fidelta is an exciting new drug discovery service company, being launched
in the
year that Croatia joins the European Union. The 100-staff team at Fidelta
have
a long history of successful drug discovery within Pliva,
GlaxoSmithKline and
Galapagos. Fidelta has extensive chemistry, pharmacology (both in vitro
and in
vivo), biomarker, toxicology and ADME/PK capabilities, with specific
experience
in inflammation, infectious, metabolic, and oncology diseases. The
company has
the know-how and resources to take projects from inception to the
clinic and
will differentiate from Argenta and BioFocus through its expertise in in
vivo
pharmacology, toxicology and inflammatory models in particular. Fidelta
will be
led by Phil Dudfield, who has extensive experience in drug discovery
within
large pharma and Galapagos and 5 years running fee-for-service
groups at
BioFocus.





"With the creation of a third service division we can offer a broader
range of
services to our customers," said Onno van de Stolpe, CEO of Galapagos.
"With
this change we can further strengthen our worldwide leadership position in
drug
discovery services, ranging from target discovery all the way through
to the
delivery of preclinical candidates, in key disease areas for our clients."



About Fidelta



Fidelta makes the difference in efficacy and safety, combining expertise in
the
areas of chemistry, pharmacology, ADME/PK and toxicology in its offering of
integrated discovery services. The company has a long history of fully
integrated drug discovery programs with primary expertise in the areas of
inflammation and anti-infective research, but has also been successful in
the
areas of oncology, CNS, cardiovascular and metabolic diseases. Fidelta's
extensive AAALAC accredited in vivo capabilities afford the possibility to
take
projects all the way to the clinic. Fidelta has more than 100 scientists
averaging over 11 years experience in the pharma industry, and more than
60%
with PhD and international experience gained at prestigious universities in
Europe and the US. More info at www.fidelta.eu : www.fidelta.eu



About Galapagos



Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage
biotechnology company specialized in the discovery and development of small
molecule and antibody therapies with a novel mode-of-action. The Company
is
progressing four clinical, six pre-clinical, and 30 discovery programs in
cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other
indications.
Its lead program is GLPG0634, an orally-available, selective inhibitor of
JAK1,
for the treatment of rheumatoid arthritis and potentially other
inflammatory
diseases. In two four-week Phase 2 studies, GLPG0634 showed improvement in
the
signs and symptoms of rheumatoid arthritis and a unique safety profile. A
6
month Phase 2b study is expected to start Q2 2013 with top line data
expected in
Q4 2014. AbbVie and Galapagos signed a worldwide license agreement whereby
AbbVie will be responsible for further development and commercialization
after
Phase 2b. Galapagos is also progressing two other clinical development
programs
with clinical readouts expected in 2013: GLPG0187, a novel integrin
receptor
antagonist in development for metastasis, is in a Phase 1b patient study;
GLPG0974 is the first inhibitor of GPR43 to be evaluated clinically for the
treatment of IBD. This program is in a second Phase 1 study and will start
a
Proof of Concept Phase 2 study in Q2 2013.



The Galapagos Group, including fee-for-service companies BioFocus, Argenta
and
Fidelta, has over 800 employees and operates facilities in five countries,
with
global headquarters in Mechelen, Belgium. Further information about the
company
and its drug development programs can be found online at: www.glpg.com : www.glpg.com



Galapagos forward-looking statements



This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and
other
factors which might cause the actual results, financial condition,
performance
or achievements of Galapagos, or industry results, to be materially
different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance
on
such forward-looking statements. These forward-looking statements speak
only as
of the date of publication of this document. Galapagos expressly disclaims
any
obligation to update any such forward-looking statements in this document
to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
unless
required by law or regulation.



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.



Source: Galapagos NV via Thomson Reuters ONE



[HUG#1670331]




Contact

Galapagos NV
Onno van de Stolpe
CEO
Tel: +31 6 2909 8028
Email Contact : www2.marketwire.com/mw/emailprcntct?id=1F2DB9F9798BB418

Fidelta
Phil Dudfield
Managing Director
Tel: +385 1 8886523



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com